51 related articles for article (PubMed ID: 26988827)
1. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.
Gao G; Xue Q; He J; Wu M; Jiang Y; Li Q; Zhang Y; Shi W
Int Immunopharmacol; 2023 Dec; 125(Pt A):111125. PubMed ID: 37907047
[TBL] [Abstract][Full Text] [Related]
2. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
[TBL] [Abstract][Full Text] [Related]
3. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
[TBL] [Abstract][Full Text] [Related]
4. Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.
Zhang J; Shi Y; Zhao M; Hu H; Huang H
Sci Rep; 2020 Aug; 10(1):14164. PubMed ID: 32843697
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic and prognostic values of flow cytometry in diffuse large B-cell lymphoma with bone marrow involvement].
Hong Y; Wan WL; Li M; Wang H; Dong F; Jing HM; Ke XY; Zhu MX
Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(29):2258-2265. PubMed ID: 37544763
[No Abstract] [Full Text] [Related]
6. Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
[TBL] [Abstract][Full Text] [Related]
7. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
8. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
Talaulikar D; Shadbolt B; Dahlstrom JE; McDonald A
J Hematol Oncol; 2009 Nov; 2():49. PubMed ID: 19930611
[TBL] [Abstract][Full Text] [Related]
9. B-ALL with synchronous MYC and BCL-2 rearrangement.
Attieh M; Asakrah S
Blood; 2023 Apr; 141(15):1894. PubMed ID: 37052936
[No Abstract] [Full Text] [Related]
10. Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.
Poynton E; Chernucha E; Day J; Prodger C; Hopkins D; Rakesh P; O'Neill T; Thakrar N; Akarca A; Jamal E; Ali A; Kirkwood AA; Pomplun S; Marafioti T; Calaminici M; Greaves P; Chaganti S; McKay P; Smith J; Eyre TA; Martinez-Calle N; Cwynarski K; Fox CP; Okosun J
Blood Adv; 2024 Apr; 8(7):1772-1775. PubMed ID: 38039509
[No Abstract] [Full Text] [Related]
11. Current challenges and novel treatment strategies in double hit lymphomas.
Anderson MA; Tsui A; Wall M; Huang DC; Roberts AW
Ther Adv Hematol; 2016 Feb; 7(1):52-64. PubMed ID: 26834954
[TBL] [Abstract][Full Text] [Related]
12. Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group.
Smock KJ; Nelson M; Tripp SR; Sanger WG; Abromowitch M; Cairo MS; Perkins SL;
Pediatr Blood Cancer; 2008 Oct; 51(4):489-94. PubMed ID: 18618503
[TBL] [Abstract][Full Text] [Related]
13. Clinical boundaries in adult cases of large B cell lymphoma with IRF4 rearrangement.
Maguire J; Harvey H; Jones A; Law R; Bashir M; O'Brien O; Sargent J; Grant C; Flavin R
Histopathology; 2024 Jan; 84(2):399-401. PubMed ID: 37876327
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
[TBL] [Abstract][Full Text] [Related]
15. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
16. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
17. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
18. MYC/BCL2 double-hit high-grade B-cell lymphoma.
Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic and cytogenetic findings of B-lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement.
Kelemen K; Holden J; Johnson LJ; Davion S; Robetorye RS
Cytometry B Clin Cytom; 2017 Jul; 92(4):310-314. PubMed ID: 26517296
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
